Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
1(13%)
Results Posted
120%(6 trials)
Terminated
2(25%)

Phase Distribution

Ph phase_2
7
88%
Ph phase_3
1
13%

Phase Distribution

0

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
7(87.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
71.4%
Most Advanced
Phase 3

Trials by Phase

Phase 27 (87.5%)
Phase 31 (12.5%)

Trials by Status

recruiting113%
terminated225%
completed563%

Recent Activity

1 active trials
Showing 5 of 8
recruitingphase_2

Haploidentical HCT for Severe Aplastic Anemia

NCT04558736
completedphase_2

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

NCT03734601
completedphase_2

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

NCT00185640
terminatedphase_3

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633
completedphase_2

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

NCT01392989
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04558736Phase 2

Haploidentical HCT for Severe Aplastic Anemia

Recruiting
NCT03734601Phase 2

Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation

Completed
NCT00185640Phase 2

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

Completed
NCT00568633Phase 3

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Terminated
NCT01392989Phase 2

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed
NCT00482053Phase 2

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Terminated
NCT00763490Phase 2

Trial Of Double Umbilical Cord Blood Transplantation

Completed
NCT00185796Phase 2

TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD

Completed

All 8 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
8